| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Hematologic System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Hematologic System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Hematologic System |
Recent Updates
Recently added Catalysts
Syndax Pharmaceuticals, Inc.$23.61
-1.23 (-4.95%)
C 57Pipeline Score Fair Value Biotech · Commercial
Market Cap
1.77 B
EPS
-2.80
P/E Ratio
-
Value Trade
22.93 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
64.86 M
R&D Expenses
58.84 M
Operating CF
-50.34 M
Total Assets
472.67 M
Total Liabilities
431.05 M
Equity
41.62 M
D/E Ratio
12,345
-2.4 %
Week
-15.15 %
1 Month
-3.39 %
3 Month
17.64 %
6 Month
10.59 %
5 Year
64.66 %
All Time
Cash Data
Cash Position
352.06 M
Monthly Burn
16.78 M
Runway
18.6 mo
Burn Trend
SEC Filing
Apr 30, 2026
Overview
Volume
2.10 M
52 Week Range
8.59 - 25.59
% held by Insiders
8.86 %
% held by Institutions
106.25 %
Enterprise Value
1.76 B
Total Shares
88.84 M
Short %
26.26 %
Float Shares
83.06 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Syndax Pharmaceuticals, Inc.
483Total events
5Upcoming
125Tier-1 (high impact)
2016 – 2026Coverage
Upcoming catalysts 5
TBD
T2Trial Initiation
Planned MenTain study: randomized placebo-controlled trial of revumenib as post-transplant maintenance
Event history 478
Jun 13, 2026
◆Poster PresentationRevumenibApprovedPresentation
Poster presentation: Revumenib as maintenance for AML following allogeneic stem cell transplantation
AML post-allogeneic stem cell transplantationsource ↗
Jun 12, 2026
◆Poster PresentationRevumenibApprovedPresentation
Poster presentation: Revumenib + venetoclax/azacitidine in newly diagnosed NPM1m or KMT2Ar AML ineligible for intensive chemotherapy: Trial in progress
newly diagnosed NPM1m or KMT2Ar AML ineligible for intensive chemotherapysource ↗
Jun 11, 2026
▲PublicationRevumenibApprovedPresentation
Publication of SAVE data in Journal of Clinical Oncology
Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AMLsource ↗
Jun 11, 2026
▲Oral PresentationRevumenibApprovedPresentation
Presentation of SAVE data at EHA 2026 Congress
Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AMLsource ↗
Jun 11, 2026
▲Oral PresentationRevumenibApprovedPresentation
Phase 2 SAVE trial of revumenib with venetoclax and decitabine/cedazuridine shows 88% ORR, 68% MRD negativity among responders, and 45% transplant rate
R/R NPM1m, KMT2Ar, or NUP98r AMLsource ↗
Jun 10, 2026
Jun 8, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
Jun 4, 2026
Jun 2, 2026
▲Oral PresentationRevumenibApprovedPresentation
Oral presentation of post-transplant revumenib maintenance data at ASCO 2026
KMT2Ar, NPM1m, or NUP98r acute leukemiasource ↗
Jun 2, 2026
▲Poster PresentationRevumenibApprovedPresentation
PK assessment of revumenib: impact of food and concomitant medications at ASCO 2026
R/R acute leukemias with KMT2Ar or NPM1msource ↗
Jun 1, 2026
◆Poster PresentationRevumenibApprovedPresentation
Phase 3 study of revumenib plus intensive chemotherapy in newly diagnosed NPM1m AML (REVEAL-ND NPM1)
Newly diagnosed NPM1m AMLsource ↗
May 27, 2026
Drug Pipeline Intelligence
C57
Pipeline Score $1.5B
Pipeline ValueFair Value
Valuation Signal6
Drugs Scored0.9x
rNPV / MCap Top 84%
Micro Cap (rank 147 of 912)
Percentile RankSyndax Pharmaceuticals, Inc. carries a moderate pipeline score (57/100), with $4.1B risk-adjusted pipeline value, led by Revumenib in Leukemia (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revumenib Small molecule | Acute Myeloid Leukemias | Phase 3 | NCT07211958 | 87% | $2.5B | RECRUITING | 468 | FAST | B (72) | Jan 1, 2031 | LOW_RISK | LOW Jun 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Revuforj BreakthroughPriorityFast Track+1 | relapsed or refractory AML | Phase 1/2 | 2026-06-11 | 88% (37/42) ORR; 71% (30/42) CRc; 60% CR/CRh (25/42); 70% (14/20) CR/CRh in venetoclax-naïve; 50% (11/22) CR/CRh in venetoclax-exposed patients; 80% (24/30) MRD negativity among evaluable CRc responders; 45% (19/42) of patients proceeding to transplant; 63% (12/19) resuming revumenib post-transplant; 14-month median overall survival; approximately 12-month median overall survival in patients with prior venetoclax exposure Read More | Syndax Announces Publication of SAVE Data on Revuforj (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology Read More | |
Revuforj BreakthroughPriorityFast Track+1 | relapsed or refractory AML | Phase 1/2 | 2026-06-11 | 88% (37/42) ORR; 71% (30/42) CRc; 60% CR/CRh (25/42); 70% (14/20) CR/CRh in venetoclax-naïve; 50% (11/22) CR/CRh in venetoclax-exposed patients; 80% (24/30) MRD negativity among evaluable CRc responders; 45% (19/42) of patients proceeding to transplant; 63% (12/19) resuming revumenib post-transplant; 14-month median overall survival; approximately 12-month median overall survival in patients with prior venetoclax exposure Read More | Syndax Announces Publication of SAVE Data on Revuforj (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology Read More | |
Revuforj BreakthroughPriorityFast Track+1 | relapsed or refractory AML | Phase 1/2 | 2026-06-11 | 88% (37/42) ORR; 71% (30/42) CRc; 60% CR/CRh (25/42); 70% (14/20) CR/CRh in venetoclax-naïve; 50% (11/22) CR/CRh in venetoclax-exposed patients; 80% (24/30) MRD negativity among evaluable CRc responders; 45% (19/42) of patients proceeding to transplant; 63% (12/19) resuming revumenib post-transplant; 14-month median overall survival; approximately 12-month median overall survival in patients with prior venetoclax exposure Read More | Syndax Announces Publication of SAVE Data on Revuforj (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SNDX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SNDX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SNDXSyndax Showcases Revuforj (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Syndax Pharmaceuticals presented promising data on its menin inhibitor Revuforj (revumenib) at EHA 2026, showing significant clinical activity in various acute leukemia subtypes. Highlights include an 82% overall response rate in a real-world study and a 97% complete remission rate in newly diagnosed patients. The results suggest that revumenib may significantly improve patient outcomes, particularly in relapsed/refractory cases. The safety profile remains consistent with previous data, with no new safety concerns reported.
Read more →SNDXSyndax Announces Publication of SAVE Data on Revuforj (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
Syndax Pharmaceuticals announced promising data from the Phase 1/2 SAVE trial, showcasing high response rates for its all-oral therapy combining Revuforj, decitabine/cedazuridine, and venetoclax in treating relapsed or refractory AML patients with specific mutations. The trial demonstrated an overall response rate of 88%, with a significant portion of patients achieving minimal residual disease negativity and a robust transplant rate. The findings were published in the Journal of Clinical Oncology, indicating potential advancements in treatment standards for menin-dependent acute leukemias.
Read more →SNDXSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals has announced the granting of inducement awards to purchase 66,700 shares of common stock to four new employees as part of its 2023 Inducement Plan. These stock options will vest over a four-year period, incentivizing employee retention and alignment with company goals. The company is known for its innovative cancer therapies, including FDA-approved products, and continues to work on advancing its pipeline through clinical trials.
Read more →SNDXSyndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
Syndax Pharmaceuticals has announced a private placement of $250 million worth of 2.25% Convertible Senior Notes due in 2031. The net proceeds, estimated at approximately $243 million, are intended for general corporate purposes, including research and development and commercialization activities. The notes will accrue interest payable semiannually and provide a conversion option for noteholders under certain conditions. J. Wood Capital Advisors LLC is the sole placement agent for the transaction. The placement underscores Syndax's efforts to strengthen its financial position in advancing innovative cancer therapies.
Read more →SNDXSyndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax Pharmaceuticals presented promising data on Revuforj® (revumenib) at ASCO 2026, highlighting a 90% two-year overall survival rate in a cohort of 24 patients with acute leukemia who resumed treatment post-transplant. The data underscores revumenib's potential in changing treatment paradigms for relapsed/refractory acute leukemia. The company plans further studies, including a randomized trial focused on post-transplant maintenance.
Read more →SNDXSyndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
Syndax Pharmaceuticals will host an R&D Day on July 14, 2026, in New York City, featuring presentations on its late-stage programs, including revumenib and axatilimab. The event will also highlight new early-stage assets and the company's broader plans to enhance treatment options. A live webcast will be available for those unable to attend in person.
Read more →SNDXSyndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Syndax Pharmaceuticals announced that four abstracts for Revuforj® (revumenib) have been accepted for presentation at the ASCO Annual Meeting 2026. Highlights include an oral presentation showcasing positive outcomes in patients with acute leukemia post-transplant. The data will also emphasize revumenib's unique pharmacokinetic profile and ongoing pivotal trials in combination with chemotherapy.
Read more →SNDXSyndax Announces Participation in Upcoming Investor Conferences
Syndax Pharmaceuticals has announced its participation in several upcoming investor conferences, including the TD Cowen 7th Annual Oncology Innovation Summit and the Jefferies Global Healthcare Conference. CEO Michael A. Metzger and the management team will engage in fireside chats at these events. The company aims to highlight its innovative cancer therapies and provide insights into its pipeline.
Read more →SNDXSyndax Highlights 12 Revuforj (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
Syndax Pharmaceuticals announced the acceptance of 12 abstracts on revumenib at the upcoming European Hematology Association Congress. These abstracts reveal strong activity of revumenib across various types of acute leukemia and highlight promising data from both monotherapy and combination treatments. Notably, the research includes favorable outcomes in post-transplant settings and suggests significant improvements in treatment metrics for acute myeloid leukemia. This presentation reinforces Syndax's potential leadership in menin inhibition therapies.
Read more →SNDXSyndax Reports First Quarter 2026 Financial Results and Provides Business Update • Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – • Revuforj (revumenib) net revenue of $48.9
Syndax Pharmaceuticals reported its first-quarter financial results for 2026, showcasing a remarkable total revenue of $64.9 million, which aligns with a 224% year-over-year increase. The company's Revuforj (revumenib) and Niktimvo (axatilimab-csfr) generated notable net revenues of $48.9 million and $55.1 million, respectively. The report emphasizes strong adoption in specific cancer treatments and anticipates new data releases and ongoing clinical trials later in the year, positioning Syndax for continued growth and market leadership.
Read more →SNDXSyndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
Syndax Pharmaceuticals announced it will report its first quarter 2026 financial results on April 30, 2026. The company will also host a conference call and webcast to discuss the results and provide a business update. Investors can access the call through a dedicated dial-in number or via a live audio webcast.
Read more →SNDXSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - March 4, 2026
Syndax Pharmaceuticals announced the grant of inducement awards for stock options to three new employees under its 2023 Inducement Plan. The awards, totaling 81,600 shares, will vest over four years, promoting employee retention. This move aligns with the company's strategy to enhance its workforce as it advances its innovative cancer therapies.
Read more →SNDXSyndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update • Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – • Revuforj (revumenib) net reve
Syndax Pharmaceuticals reported robust financial results for Q4 and full year 2025, achieving total revenues of $68.7 million and $172.4 million, respectively. Key drivers included significant growth in net revenues for Revuforj and Niktimvo, alongside ongoing clinical developments. The company successfully completed enrollment in a Phase 2 trial for axatilimab, with topline data expected in Q4 2026. Additionally, Syndax highlighted the continued demand for Revuforj following its recent FDA approval, positioning itself for further growth in 2026.
Read more →SNDXSyndax Announces Participation in March Investor Conferences
Syndax Pharmaceuticals announced its participation in upcoming investor conferences, featuring CEO Michael A. Metzger and the management team. The company will provide live webcasts of the events on its website. Syndax is known for its innovative cancer therapies, including FDA-approved treatments like Revuforj and Niktimvo.
Read more →SNDXSyndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026
Syndax Pharmaceuticals has announced it will report its fourth quarter and full year 2025 financial results on February 26, 2026. The management team will also host a conference call and live webcast at that time to provide a business update. Investors can participate via phone or access the webcast through the company's website, with a replay available afterward. The company is noted for its commitment to developing innovative cancer therapies and is conducting various clinical trials.
Read more →SNDXSyndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
Syndax Pharmaceuticals announced its participation in the 2026 Guggenheim Emerging Outlook: Biotech Summit, where CEO Michael A. Metzger will engage in a fireside chat. The event is scheduled for February 12, 2026, and will include a live webcast available on the company's website. Syndax continues to advance its innovative cancer therapies, including FDA-approved treatments.
Read more →SNDXSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - February 4, 2026
Syndax Pharmaceuticals announced the grant of inducement awards for stock options to two new employees under its 2023 Inducement Plan. The awards, totaling up to 11,600 shares, will vest over four years, reflecting the company's commitment to attracting talent. Syndax continues to advance its pipeline of innovative cancer therapies, including FDA-approved treatments.
Read more →SNDXSyndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44 th Annual J.P. Morgan Healthcare Conference – Approximately $44 million and $125 million in preliminary (unaudited) Revu
Syndax Pharmaceuticals reported preliminary, unaudited financial highlights for 2025 during the 44th Annual J.P. Morgan Healthcare Conference. The company achieved approximately $125 million in net revenue for Revuforj, marking a significant growth of 38% in the last quarter compared to the previous quarter. Additionally, the company initiated several important clinical trials and announced plans for growth and profitability in the upcoming year. With a cash reserve of about $394 million, Syndax appears well-positioned for future expansion and the advancement of its product portfolio.
Read more →SNDX▲ +8.7%on this newsshared move
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
Syndax Pharmaceuticals and the World Orphan Drug Alliance have announced a Managed Access Program to expand the availability of Revuforj (revumenib) in regions where it is not commercially available. This initiative will cover parts of Eurasia, Europe, Israel, the Middle East, Latin America, and Africa. The program aims to provide patients with access to this first-in-class menin inhibitor while allowing physicians to gain experience with the drug.
Read more →SNDX▼ -5.1%on this newsshared move
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Syndax Pharmaceuticals announced that CEO Michael A. Metzger will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will be available via live webcast and later as a replay. The company is known for its innovative cancer therapies, including FDA-approved treatments.
Read more →SNDXRevuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
Syndax Pharmaceuticals' Revuforj (revumenib) has been recognized as Best New Drug at the Scrip Awards 2025. This first-in-class menin inhibitor recently received FDA approval for treating relapsed or refractory acute leukemia and acute myeloid leukemia. The award highlights the drug's innovative approach and potential benefits for patients with specific genetic mutations.
Read more →SNDXSyndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
Syndax Pharmaceuticals presented promising data on Revuforj (revumenib) at the 67th ASH Annual Meeting, highlighting its efficacy and safety in treating various acute leukemia subtypes. Key findings include a 77% overall response rate and favorable tolerability in real-world settings. The company is advancing multiple trials to expand the clinical data supporting Revuforj's use in frontline settings.
Read more →SNDXSyndax Announces Participation at the 8th Annual Evercore Healthcare Conference
Syndax Pharmaceuticals announced its participation in the 8th Annual Evercore Healthcare Conference, where CEO Michael A. Metzger will engage in a fireside chat. The event is scheduled for December 4, 2025, at 11:15 a.m. ET. A live webcast will be available on the company's website, along with a replay for a limited time.
Read more →SNDX▲ +11.6%on this newsshared move
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
Syndax Pharmaceuticals reported a strong third quarter in 2025, achieving $45.9 million in total revenue, a 21% increase from the previous quarter. The company highlighted the FDA approval of Revuforj for R/R NPM1m AML and a significant rise in demand for both Revuforj and Niktimvo. Despite a net loss of $60.7 million, Syndax maintains a robust cash position of $456.1 million, supporting its path to profitability.
Read more →SNDXSyndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
Syndax Pharmaceuticals announced that 23 abstracts, including six oral presentations, have been accepted for the 67th American Society of Hematology Annual Meeting in December 2025. The data highlights the promising efficacy of Revuforj in treating various acute leukemia subtypes and the potential of Niktimvo for long-term benefits in chronic GVHD. The company will also host an investor event during the meeting.
Read more →SNDXSyndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
Syndax Pharmaceuticals announced an in-person investor event on December 8, 2025, coinciding with the ASH Annual Meeting. The event will include discussions on updates from their Revuforj® and Niktimvo™ programs, featuring key opinion leaders. A live webcast will be available for those unable to attend in person.
Read more →SNDXSyndax Announces Participation in November Investor Conferences
Syndax Pharmaceuticals has announced that CEO Michael A. Metzger and the management team will participate in upcoming investor conferences. The company aims to enhance its visibility and engage with investors through live webcasts. Syndax is known for its innovative cancer therapies, including FDA-approved treatments like Revuforj® and Niktimvo™.
Read more →SNDXSyndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
Syndax Pharmaceuticals has announced that it will report its third quarter 2025 financial results on November 3, 2025. The company will also host a conference call and live audio webcast to discuss these results and provide a business update. Interested parties can access the webcast through the company's website, and a replay will be available afterward.
Read more →SNDX▼ -11.1%on this newsshared move
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
Syndax Pharmaceuticals announced FDA approval for Revuforj (revumenib) to treat relapsed or refractory acute myeloid leukemia (AML) with an NPM1 mutation in patients aged one year and older. This marks the first therapy approved for both NPM1 mutated AML and KMT2A translocated acute leukemia. The approval is based on positive results from the AUGMENT-101 trial, highlighting Revuforj's efficacy and safety profile.
Read more →SNDX▼ -7.8%on this newsshared move
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update • $45.9 million in total revenue, representing 21% growth over 2Q25 – • $32.0 million Revuforj (revumenib) net revenue
Syndax Pharmaceuticals reported a strong financial performance for Q3 2025, with total revenues of $45.9 million, reflecting a 21% increase from the previous quarter. The company highlighted the successful FDA approval of Revuforj for treating acute myeloid leukemia and continued strong demand for both Revuforj and Niktimvo. Additionally, Syndax is pursuing multiple trials for its drug candidates and expects significant developments in the near future. Despite a decrease in R&D expenses, driven by the absence of prior milestone payments, the outlook for Syndax remains positive.
Read more →SNDXSyndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
Syndax Pharmaceuticals announced that revumenib has been included in the NCCN Clinical Practice Guidelines as a category 2A recommendation for treating relapsed or refractory NPM1 mutated acute myeloid leukemia. This update follows positive results from the AUGMENT-101 trial. The FDA has also granted Priority Review for revumenib's supplemental New Drug Application, with a target action date of October 25, 2025.
Read more →SNDXSyndax Announces Participation in September Investor Conferences
Syndax Pharmaceuticals announced its participation in two upcoming investor conferences, showcasing its engagement with the investment community. CEO Michael A. Metzger and the management team will be present at Citi's BioPharma Back to School Conference and H.C. Wainwright's Global Investment Conference in September 2025. The company highlighted its innovative cancer therapies, including FDA-approved treatments such as Revuforj® and Niktimvo™. Live webcasts of the presentations will be available on their website.
Read more →SNDXSyndax Reports Second Quarter 2025 Financial Results and Provides Business Update • $28.6 million of Revuforj (revumenib) net revenue, representing 43% growth over 1Q25 – • $36.2 million of Niktimvo
Syndax Pharmaceuticals announced its financial results for Q2 2025, highlighting impressive growth in net revenues from its products Revuforj and Niktimvo. Revuforj generated $28.6 million in net revenue, experiencing a 43% increase compared to the previous quarter. The company is expecting approval for Revuforj as the first treatment for relapsed/refractory mutant NPM1 acute myeloid leukemia by October 2025. Niktimvo reached $36.2 million in net revenue in its first full quarter, indicating a strong market response and early profitability potential.
Read more →SNDXSyndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
Syndax Pharmaceuticals has announced that it will report its financial results for the second quarter of 2025 and provide a business update on August 4, 2025. The event will include a conference call hosted by the company's management and will be accessible via a live audio webcast. Syndax, known for its innovative cancer therapies, highlights its pipeline, including FDA-approved treatments such as Revuforj® and Niktimvo™. A replay of the conference call will be available following the live event.
Read more →SNDXSyndax Announces FDA Priority Review of sNDA for Revuforj (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
Syndax Pharmaceuticals has announced that the FDA granted Priority Review for its supplemental New Drug Application (sNDA) for Revuforj (revumenib) to treat relapsed or refractory mutant NPM1 acute myeloid leukemia (mNPM1 AML). The sNDA is under evaluation in the FDA's Real-Time Oncology Review program, with a target action date set for October 25, 2025. Revuforj is already approved for a related indication and, if successful, this application could expand its use to a broader group of patients. The application is backed by positive data from the AUGMENT-101 trial, highlighting Revuforj's promising role in an area with significant unmet needs.
Read more →SNDXSyndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
Syndax Pharmaceuticals announced the publication of positive data from the BEAT AML trial evaluating revumenib combined with venetoclax and azacitidine in older patients with mutant NPM1 (mNPM1) and KMT2A-rearranged acute myeloid leukemia (AML). The trial showed promising results, with a 67% complete remission rate and 100% MRD negativity among responders. Revumenib’s favorable safety profile and its observations position it as a significant therapy option for patients unfit for intensive chemotherapy. The company is currently moving forward with enrollment in a pivotal Phase 3 trial evaluating the efficacy of this combination treatment.
Read more →SNDXSyndax Presents New Revuforj (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
Syndax Pharmaceuticals has presented new data from the AUGMENT-101 trial of Revuforj (revumenib) at the 2025 EHA Annual Congress. The results show a 26% complete remission plus complete remission with partial hematologic recovery (CR+CRh) rate and a 48% overall response rate (ORR) in patients with relapsed or refractory mutant NPM1 acute myeloid leukemia (AML). The safety profile was consistent with earlier findings, indicating the treatment was generally well-tolerated. This data supports the potential of revumenib as a standard treatment for R/R mNPM1 AML, building on previous FDA approval for another acute leukemia subtype.
Read more →SNDXSyndax Announces Participation in June Investor Conferences
Syndax Pharmaceuticals has announced its participation in two key investor conferences in June 2025. CEO Michael A. Metzger and the management team will engage in discussions at the Jefferies Global Healthcare Conference and the Goldman Sachs 46th Annual Global Healthcare Conference. The company, known for its innovative cancer therapies, aims to increase its visibility and showcase its developments, including FDA-approved drugs Revuforj and Niktimvo. Live webcasts of these discussions will be accessible on the company's website.
Read more →SNDX▼ -8.9%on this news
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj (revumenib) and Niktimvo™ (axatilimab-csfr)
Syndax Pharmaceuticals announced the acceptance of multiple abstracts for its drugs Revuforj (revumenib) and Niktimvo (axatilimab-csfr) at the upcoming EHA 2025 Annual Congress. The abstracts will highlight significant developments in treating acute leukemia and chronic GVHD, focusing on updated trial results and patient responses. The company anticipates that the presentation of its data, particularly regarding Revuforj's efficacy, will stimulate further interest from healthcare professionals in ongoing clinical trials.
Read more →SNDXSyndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer - Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug d
Syndax Pharmaceuticals has appointed Dr. Nicholas Botwood as its new Head of Research and Development and Chief Medical Officer. Dr. Botwood, who previously headed Worldwide Medical Oncology at Bristol Myers Squibb, brings over 25 years of industry experience. He succeeds Dr. Neil Gallagher, who is leaving to pursue other opportunities. The company highlighted Dr. Botwood's strategic and operational expertise in oncology, which it expects will bolster the growth of its oncology product franchises.
Read more →SNDX▲ +10.2%on this newsshared move
Syndax Announces Participation in May Investor Conferences
Syndax Pharmaceuticals announced its participation in upcoming investor conferences, featuring CEO Michael A. Metzger and the management team. They will engage in discussions at the Bank of America Merrill Lynch Vegas Health Care Conference on May 15, 2025, and at the TD Cowen 6th Annual Oncology Innovation Summit on May 28, 2025. These events reflect Syndax's ongoing commitment to advancing its innovative cancer therapies and engaging with potential investors.
Read more →SNDX▼ -6.1%on this newsshared move
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
Syndax Pharmaceuticals announced the publication of pivotal trial data for revumenib, a first-in-class menin inhibitor, for the treatment of relapsed or refractory mNPM1 acute myeloid leukemia (AML) in the journal Blood. The AUGMENT-101 trial reported an overall response rate of nearly 50% in a heavily pre-treated patient population, meeting its primary efficacy endpoint. Following these positive results, Syndax submitted a supplemental New Drug Application to the FDA, aiming to advance revumenib's treatment applications in AML, which currently lacks targeted therapies.
Read more →SNDXSyndax Reports First Quarter 2025 Financial Results and Provides Business Update • $20.0 million in Revuforj (revumenib) net revenue in first full quarter of launch – • $13.6 million in Niktimvo (axa
Syndax Pharmaceuticals announced its financial results for Q1 2025, reporting $20 million in net revenue for Revuforj and $13.6 million for Niktimvo. The company has opened enrollment in pivotal trials for revumenib aimed at treating specific forms of acute leukemia. Additionally, Syndax is maintaining a strong cash position of $602.1 million to support ongoing and future initiatives, although it faced a commercial loss from Niktimvo. Overall, the financial disclosures demonstrate healthy engagement in the market and ongoing development activities.
Read more →SNDXSyndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025
Syndax Pharmaceuticals has announced its plan to report first quarter 2025 financial results on May 5, 2025. In conjunction with this announcement, the company will hold a conference call and live audio webcast for investors to discuss the financial results and provide a business update. Syndax is recognized for its innovative pipeline of cancer therapies, including FDA-approved drugs like Revuforj and Niktimvo. The company aims to engage with its stakeholders and enhance transparency through this communication.
Read more →SNDX▲ +8%on this newsshared move
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
Syndax Pharmaceuticals has announced its participation in the Stifel 2025 Virtual Targeted Oncology Forum, with CEO Michael A. Metzger and management team members set to take part in a fireside chat. This event is scheduled for April 9, 2025, and will include a live webcast available on the company’s investor website. Syndax is focused on developing a robust pipeline of cancer therapies, featuring notable FDA-approved products like Revuforj® and Niktimvo™. The firm's commitment to cancer treatment innovation is reflected in its ongoing clinical trials.
Read more →SNDXSyndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update • $7.7 million in Revuforj (revumenib) net product revenue in initial five weeks of launch – • Launched
Syndax Pharmaceuticals reported its financial results for Q4 and FY 2024, highlighting a strong debut with Revuforj, which generated $7.7 million in net revenue within five weeks of launch. The company also launched Niktimvo, an approved treatment for chronic graft-versus-host disease, in January 2025, while reporting significant financial resources to sustain its operations. Anticipated milestones include an sNDA filing for revumenib in the second quarter of 2025 based on promising trial outcomes, positioning Syndax for potential growth and profitability.
Read more →SNDXSyndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
Syndax Pharmaceuticals announced it will report its fourth quarter and full year 2024 financial results on March 3, 2025. A conference call and live audio webcast will accompany the earnings release, allowing stakeholders to discuss the financial outcomes and business updates. The company continues to advance its pipeline of cancer therapies, including FDA-approved drugs. A replay of the event will be available on the company's website for those unable to attend live.
Read more →SNDXSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced inducement grants for six new employees, allowing them to purchase up to 124,000 shares of common stock. These stock options will vest over four years, promoting employee retention. The company continues to develop its innovative cancer therapy pipeline, which includes FDA-approved treatments.
Read more →SNDXSyndax Announces Participation in February Investor Conferences Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced its participation in two upcoming investor conferences. CEO Michael A. Metzger and the management team will engage in fireside chats at the Guggenheim SMID Cap Biotech Conference and Citi's Virtual Oncology Leadership Summit. The events aim to showcase Syndax's innovative cancer therapies and provide insights into their pipeline.
Read more →SNDXSyndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference – Launched Revuforj® (revumenib) for treatment of R/R acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older –...
Syndax Pharmaceuticals presented its recent achievements and future goals at the 43rd Annual J.P. Morgan Healthcare Conference. Key highlights include the launch of Revuforj (revumenib) for treating R/R acute leukemia and the FDA approval of Niktimvo (axatilimab) for chronic GVHD. The company anticipates significant milestones in 2025, including a supplemental NDA filing for revumenib and further clinical trial data releases.
Read more →SNDXSyndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. CEO Michael A. Metzger will lead the presentation, which will be available via live webcast. The company is known for its innovative cancer therapies, including FDA-approved treatments like Revuforj® and Niktimvo™.
Read more →SNDX▼ -8.5%on this news· ran to -21% by day 3
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial – Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64) show responses across all major subgroups, including heavily...
Syndax Pharmaceuticals announced promising results from the AUGMENT-101 and BEAT AML trials for Revuforj (revumenib) in treating relapsed or refractory mNPM1 AML. The Phase 2 trial showed a 26% complete remission rate and a 48% overall response rate. In the BEAT AML trial, 100% overall response and 95% complete remission rates were achieved with Revuforj in combination with venetoclax and azacitidine. The data suggest Revuforj's potential to significantly improve treatment outcomes for AML patients.
Read more →SNDX▼ -8.5%on this news· ran to -21% by day 3shared move
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting – 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in ...
Syndax Pharmaceuticals presented promising data on Revuforj® (revumenib) at the 66th ASH Annual Meeting, showcasing an 82% overall response rate in the SAVE trial for acute leukemias. The drug demonstrated rapid and durable responses across various patient subgroups, supporting its potential for further combination trials. Revumenib is FDA-approved for treating relapsed or refractory acute leukemia with KMT2A translocation.
Read more →SNDXSyndax Announces Participation at the Citi 2024 Global Healthcare Conference Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced that CEO Michael A. Metzger will participate in a panel discussion at the Citi 2024 Global Healthcare Conference on December 5, 2024. The discussion will focus on novel mechanisms in oncology. The event will be accessible via a live webcast on the company's website.
Read more →SNDX▼ -5.7%on this news
Syndax Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation – Approval base
Syndax Pharmaceuticals has received FDA approval for Revuforj (revumenib), the first menin inhibitor to treat relapsed or refractory acute leukemia with a KMT2A translocation. This approval is based on positive outcomes from the AUGMENT-101 clinical trial, demonstrating significant rates of remission among patients. Revuforj will be commercially available in various dosages, with personalized support programs established for patients. However, the treatment is associated with potential risks, including differentiation syndrome, underscoring the need for careful patient management.
Read more →SNDX▼ -5.7%on this news
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the...
Syndax Pharmaceuticals announced FDA approval for Revuforj (revumenib), the first menin inhibitor for treating relapsed or refractory acute leukemia with a KMT2A translocation in patients aged one year and older. The approval is based on positive results from the AUGMENT-101 clinical trial, demonstrating significant remission rates. Syndax plans to launch Revuforj this month, enhancing treatment options for this aggressive leukemia type.
Read more →SNDX▼ -25.6%on this newsshared move
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib – Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients (p-value = 0.0014) – – 47% (30/64) ORR in a heavily...
Syndax Pharmaceuticals announced positive topline results from the AUGMENT-101 trial, demonstrating a 23% complete remission rate in patients with relapsed or refractory mNPM1 AML. The trial met its primary endpoint, with a notable overall response rate of 47%. The safety profile was favorable, with low treatment discontinuation rates. An sNDA filing for mNPM1 AML is expected in the first half of 2025.
Read more →SNDX▼ -25.6%on this newsshared move
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib – Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 A
Syndax Pharmaceuticals announced positive topline results from the AUGMENT-101 trial, highlighting a 23% complete remission rate in patients with relapsed or refractory mutant NPM1 acute myeloid leukemia. The overall response rate stood at 47%, demonstrating the efficacy of the menin inhibitor revumenib. Patient safety was confirmed, with only 5% discontinuing treatment due to adverse events. The company anticipates submitting a supplemental NDA for this indication in the first half of 2025 following the FDA's expected approval for another indication.
Read more →SNDXSyndax Reports Third Quarter 2024 Financial Results and Provides Business Update – New revumenib and Niktimvo™ clinical data will be highlighted at 66th ASH Annual Meeting – – mNPM1 AML topline data from AUGMENT-101 expected in...
Syndax Pharmaceuticals reported its Q3 2024 financial results, highlighting significant advancements in its pipeline, including the FDA approval of Niktimvo for chronic GVHD and the ongoing review of revumenib for acute leukemia. The company anticipates key data releases and has secured substantial funding to support its operations. Despite increased losses, Syndax is positioned for growth with upcoming product launches.
Read more →SNDXSyndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024 Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced an in-person investor event on December 9, 2024, during the ASH Annual Meeting in San Diego. The event will include discussions on updates from the company's cancer therapies, revumenib and Niktimvo. A live webcast will be available for those unable to attend in person.
Read more →SNDXSyndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting Syndax Pharmaceuticals (Nasdaq:SNDX), today announced that multiple abstracts evaluating Niktimvo™ (axatilimab-csfr), an anti-CSF-1R antibody for the ...
Syndax Pharmaceuticals announced that multiple abstracts on Niktimvo (axatilimab-csfr) will be presented at the 66th ASH Annual Meeting. The data includes a secondary analysis from the AGAVE-201 trial, showing significant response rates in chronic graft-versus-host disease (GVHD) patients. The company aims to advance treatment options for chronic GVHD and other fibrotic diseases. An investor event will also be held during the meeting to discuss the latest findings.
Read more →SNDXSyndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been...
Syndax Pharmaceuticals announced that multiple abstracts on revumenib, an oral menin inhibitor, will be presented at the 66th ASH Annual Meeting. The data highlights revumenib's efficacy in treating acute leukemias, showing a 64% overall response rate in KMT2Ar acute leukemia and an 88% response rate in combination therapies. The FDA has granted Priority Review for revumenib's NDA, with a target action date of December 26, 2024.
Read more →SNDXSyndax Reports Third Quarter 2024 Financial Results and Provides Business Update – New revumenib and Niktimvo clinical data will be highlighted at 66 th ASH Annual Meeting – – mNPM1 AML topline data
Syndax Pharmaceuticals reported its financial results for Q3 2024, highlighting key developments in its pipeline. The company anticipates the FDA's decision on revumenib for acute leukemia by December 2024 and plans to file a supplemental NDA based on upcoming clinical data. Niktimvo has received FDA approval for treating chronic GVHD and is set to launch by early 2025, bolstered by a $350 million funding agreement. The company is positioned to achieve profitability, with multiple trials indicating positive outcomes for its innovative cancer therapies.
Read more →SNDXSyndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million synthetic...
Syndax Pharmaceuticals has entered a $350 million royalty funding agreement with Royalty Pharma to support the launch and development of its drug Niktimvo™ for chronic graft-versus-host disease (GVHD). This funding is expected to help Syndax reach profitability while retaining profit participation from Niktimvo. The drug is anticipated to launch in the U.S. by early 2025.
Read more →SNDXSyndax Announces Participation in November Investor Conferences Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals has announced its participation in several upcoming investor conferences, including the Guggenheim's Inaugural Healthcare Innovation Conference and the UBS Global Healthcare Conference. CEO Michael A. Metzger and the management team will engage in fireside chats to discuss the company's innovative cancer therapies. Webcasts of these events will be available on the company's website.
Read more →SNDXSyndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024 Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced it will report its third quarter 2024 financial results on November 5, 2024. The company will also host a conference call and live audio webcast to discuss the results and provide a business update. Interested parties can access the webcast through the company's website or join via a conference call.
Read more →SNDXSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced the grant of inducement awards for stock options to five new employees under its 2023 Inducement Plan. The awards, totaling up to 62,700 shares, will vest over four years, promoting employee retention. This move reflects the company's commitment to expanding its workforce as it develops its cancer therapy pipeline.
Read more →SNDXIncyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease – Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg every 2 weeks dose achieving a complete or partial...
Incyte and Syndax announced the publication of pivotal Phase 2 AGAVE-201 trial results for Niktimvo (axatilimab-csfr) in chronic graft-versus-host disease (GVHD). The trial met its primary endpoint, with 74% of patients achieving a response. Niktimvo has been approved by the FDA for patients who have failed prior therapies and is now included in the NCCN guidelines.
Read more →SNDXSyndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced the publication of pivotal AUGMENT-101 trial data for revumenib in KMT2Ar acute leukemia in the Journal of Clinical Oncology. The trial met its primary endpoint, leading to an NDA filing under the FDA's Real-Time Oncology Review program, with a target action date of December 26, 2024. The results show promise for both adult and pediatric patients with relapsed/refractory KMT2Ar acute leukemia.
Read more →SNDX▼ -6.6%on this news
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced the grant of inducement awards for 104,600 shares of common stock to nine new employees as part of its 2023 Inducement Plan. The stock options will vest over four years, reflecting the company's commitment to attracting talent while advancing its innovative cancer therapy pipeline. This move indicates growth and investment in the company's future.
Read more →SNDXSyndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals reported its Q2 2024 financial results, highlighting significant advancements in its clinical pipeline. The company has received Priority Review for axatilimab's BLA and is awaiting the PDUFA action date. Additionally, the NDA for revumenib is under Real-Time Oncology Review, with topline data from the AUGMENT-101 trial expected later this year. Despite these advancements, the company reported a net loss of $68.1 million for the quarter.
Read more →SNDXSyndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update – Axatilimab BLA in refractory chronic GVHD is under Priority Review; PDUFA action date of
Syndax Pharmaceuticals reported its second quarter 2024 financial results and notable advancements in its drug pipeline. The company is under FDA Priority Review for its axatilimab BLA targeting refractory chronic GVHD with a PDUFA action date set for August 28, 2024. Revumenib is also progressing with its NDA for KMT2Ar acute leukemia, receiving Priority Review with a new PDUFA date of December 26, 2024. Despite reporting increased net losses and elevated expenses, Syndax maintains a positive outlook with upcoming data releases and ongoing clinical trials.
Read more →SNDX▼ -10.2%on this newsshared move
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced that the FDA has extended the PDUFA action date for revumenib's NDA to December 26, 2024. This extension allows the FDA additional time to review supplemental information provided by Syndax. Revumenib is being developed for treating relapsed or refractory KMT2Ar acute leukemia and has received several designations from the FDA.
Read more →SNDXSyndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced it will report its second quarter 2024 financial results on August 1, 2024. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. A replay will be available for those unable to attend.
Read more →SNDXSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced the granting of inducement awards for 124,000 shares of common stock to eight new employees under its 2023 Inducement Plan. The stock options will vest over four years, promoting employee retention. This move signals the company's commitment to growth and innovation in its cancer therapy pipeline.
Read more →SNDXSyndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals presented updated data on revumenib at the EHA 2024 Congress, showing promising results in combination trials for acute leukemias. The BEAT AML trial reported a 96% complete remission rate in newly diagnosed patients, while the AUGMENT-102 trial demonstrated efficacy in relapsed/refractory cases. The company plans to initiate a pivotal trial by the end of 2024.
Read more →SNDXSyndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals has progressed to the Phase 1b portion of its trial for revumenib, a menin inhibitor, in patients with relapsed or refractory metastatic MSS colorectal cancer. This decision follows a favorable safety profile and promising efficacy signals from the Phase 1a trial. The trial aims to assess the drug's safety and anti-tumor activity in this patient population.
Read more →SNDXSyndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, where CEO Michael A. Metzger will engage in a fireside chat. The event is scheduled for June 12, 2024, at 8:40 a.m. ET, and will be accessible via a live webcast. Syndax is known for its innovative cancer therapy pipeline.
Read more →SNDXSyndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
Syndax Pharmaceuticals has appointed Dr. Aleksandra Rizo to its Board of Directors, effective soon after the departure of Dr. Briggs Morrison. Dr. Rizo brings a wealth of experience with a successful track record in hematology drug development, and she will serve on the Science and Technology Committee. The company anticipates launching two novel cancer therapies this year, and Dr. Rizo's expertise is expected to be invaluable during this transition to a commercial stage. Her prior leadership roles at various biopharmaceutical companies support her suitability for this position.
Read more →SNDXSyndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals has appointed Dr. Aleksandra Rizo to its Board of Directors, replacing Dr. Briggs Morrison. Dr. Rizo brings significant experience in clinical development, particularly in hematology. Her appointment comes as Syndax prepares for the potential launch of two new cancer therapies in 2024. The Board expresses confidence in her ability to contribute to the company's growth.
Read more →SNDXSyndax Announces Participation at the Bank of America Securities 2024 Health Care Conference Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced its participation in the Bank of America Securities 2024 Health Care Conference, scheduled for May 16, 2024. Members of the management team will engage in a fireside chat, which will be accessible via a live webcast. The company is known for its innovative cancer therapies, including revumenib and axatilimab.
Read more →SNDXSyndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals reported its Q1 2024 financial results, highlighting significant progress in its clinical pipeline, including Priority Review designations for revumenib and axatilimab. The company completed enrollment in the AUGMENT-101 trial and anticipates key data in late 2024. Despite a net loss of $72.4 million, Syndax remains optimistic about upcoming milestones.
Read more →SNDXSyndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update – NDA filing for revumenib in R/R KMT2Ar acute leukemia granted Priority Review under RTOR; PDUFA actio
Syndax Pharmaceuticals reported its first quarter 2024 financial results, highlighting significant developments in its clinical pipeline. The NDA filing for revumenib in relapsed or refractory KMT2A-rearranged acute leukemia has been granted Priority Review by the FDA, with a PDUFA action date set for September 26, 2024. Additionally, the company completed enrollment in its pivotal AUGMENT-101 trial, with topline data expected in the fourth quarter, potentially leading to a supplemental NDA filing in 2025. Despite a reported net loss of $72.4 million, Syndax signals a strong position heading into a year of key milestones.
Read more →SNDXSyndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals will report its first quarter 2024 financial results on May 8, 2024. The company will also host a conference call and webcast to discuss these results and provide a business update. Interested parties can access the live event through the company's website or via dial-in numbers. A replay will be available afterward.
Read more →SNDXSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced that CEO Michael A. Metzger will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on April 17, 2024. This event highlights Syndax's commitment to advancing its cancer therapy pipeline, including drugs like revumenib and axatilimab. A live webcast will be available on their website.
Read more →SNDXSyndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session Syndax Pharmaceuticals (NASDAQ: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced positive data from the AUGMENT-101 trial, showcasing the efficacy and safety of revumenib in pediatric patients with relapsed/refractory KMT2Ar acute leukemia. The trial results were presented at the ASPHO Conference, highlighting a 23% complete remission rate and a well-tolerated safety profile. The findings support revumenib's potential as a treatment option for this vulnerable patient population.
Read more →SNDXSyndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals has announced the completion of enrollment in the AUGMENT-101 pivotal trial for relapsed/refractory mNPM1 acute myeloid leukemia. Topline data is anticipated in Q4 2024, which may support a supplemental New Drug Application for revumenib in early 2025. The trial aims to evaluate the drug's efficacy and safety in a significant patient population.
Read more →SNDXSyndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced that the FDA has granted Priority Review for its New Drug Application (NDA) for revumenib, a first-in-class menin inhibitor aimed at treating relapsed or refractory KMT2A-rearranged acute leukemia. The NDA is supported by positive results from the AUGMENT-101 trial, which demonstrated promising efficacy rates. The target action date for the NDA is set for September 26, 2024.
Read more →SNDX▼ -6.8%on this news
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer – Steven Closter brings more than 30 years of commercial experience in the biopharmaceutical industry to Syndax – – Company
Syndax Pharmaceuticals has appointed Steven Closter as its new Chief Commercial Officer, effective immediately. With over 30 years of experience in the biopharmaceutical industry, Closter will lead the company's commercial strategy as Syndax prepares for two significant product launches in 2024. He succeeds Steve Sabus, who has departed for personal reasons. CEO Michael A. Metzger expressed confidence in Closter's ability to enhance the commercial organization for these upcoming launches.
Read more →SNDXSyndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update – BLA filing for axatilimab in chronic GVHD granted Priority Review; PDUFA action date s
Syndax Pharmaceuticals has reported its financial results for Q4 and the full year of 2023, highlighting key clinical and regulatory updates. The company’s Biologics License Application (BLA) for axatilimab in chronic GVHD has been granted Priority Review, with a PDUFA date set for August 2024. Additionally, an NDA for revumenib in relapsed/refractory KMT2A-rearranged acute leukemia has been submitted under the FDA’s RTOR program, with further action expected soon. Despite a reported increase in net losses and R&D expenses, Syndax's financial position remains strong with adequate funds to support operations until 2026.
Read more →SNDXSyndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update – BLA filing for axatilimab in chronic GVHD granted Priority Review; PDUFA action date set for August 28, 2024 – – NDA for revumenib in R/R KMT2Ar...
Syndax Pharmaceuticals reported its financial results for Q4 and full year 2023, highlighting significant milestones in its clinical pipeline. The FDA granted Priority Review for the BLA filing of axatilimab for chronic GVHD, with a PDUFA action date set for August 28, 2024. Additionally, the NDA for revumenib in R/R KMT2Ar acute leukemia was submitted under the RTOR program, with expectations for a PDUFA date in Q1 2024.
Read more →SNDX▲ +5.4%on this newsshared move
Syndax Announces Participation at Two Upcoming Investor Conferences Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals has announced participation in two upcoming investor conferences. The management team will engage in a fireside chat and a corporate panel discussion at TD Cowen's 44th Annual Health Care Conference, followed by another fireside chat at the Barclays Global Healthcare Conference. Live webcasts of these sessions will be available on the company's website.
Read more →SNDXSyndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024 Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals will announce its fourth quarter and year-end 2023 financial results on February 27, 2024. Following the earnings release, the company will host a conference call and live audio webcast to discuss the results and provide a business update. The event will be accessible via the company's website.
Read more →SNDXSyndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced that its CEO, Michael A. Metzger, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. The presentation will highlight the company's innovative cancer therapy pipeline, including key products like revumenib and axatilimab. A live webcast of the event will be available on the company's website.
Read more →SNDXSyndax Highlights Recent Updates and Anticipated 2024 Milestones Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals has announced significant updates and milestones for 2024, including the submission of a New Drug Application for revumenib for treating relapsed or refractory KMT2Ar acute leukemia. The company also submitted a Biologics License Application for axatilimab for chronic graft-versus-host disease. Positive data from pivotal trials were presented at the recent ASH Annual Meeting, and Syndax has extended its cash runway through 2026.
Read more →SNDXSyndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Syndax Pharmaceuticals, Inc. has successfully closed its public offering of 12,432,431 shares of common stock, including the full exercise of the underwriters' option for an additional 1,621,621 shares. The offering generated approximately $230 million in gross proceeds at a price of $18.50 per share. Syndax’s current total shares outstanding is 84,809,736 following the offering, which was facilitated by multiple leading financial institutions. The shares were offered under a previously filed registration statement with the SEC, ensuring compliance with regulatory requirements.
Read more →SNDXSyndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative...
Syndax Pharmaceuticals has successfully closed its public offering of 12,432,431 shares, raising approximately $230 million. The offering included the full exercise of the underwriters' option to purchase additional shares. The funds will support the company's innovative cancer therapy pipeline, which includes key products like revumenib and axatilimab.
Read more →SNDX▲ +6.7%on this newsshared move
Syndax Announces Pricing of $200 Million Public Offering of Common Stock Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...
Syndax Pharmaceuticals has announced a public offering of 10,810,810 shares of common stock at $18.50 per share, aiming to raise approximately $200 million. The offering is set to close on December 19, 2023, pending customary conditions. Goldman Sachs, J.P. Morgan, and others are managing the offering, which is registered under an effective SEC statement.
Read more →SNDX▲ +6.7%on this newsshared move
Syndax Announces Proposed $150 Million Public Offering of Common Stock Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...
Syndax Pharmaceuticals announced a proposed public offering of $150 million in common stock, with an option for underwriters to purchase an additional 15%. The offering is subject to market conditions and will be conducted under an existing SEC registration statement. The company continues to develop its innovative cancer therapy pipeline.
Read more →SNDXSyndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting – Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); CR/CRh rate...
Syndax Pharmaceuticals presented positive interim results from the AUGMENT-101 trial of revumenib for relapsed/refractory KMT2Ar acute leukemia at the 65th ASH Annual Meeting. The trial met its primary endpoint with a 23% complete remission rate and an overall response rate of 63%. Revumenib demonstrated a favorable safety profile with low discontinuation rates. The company plans to submit a New Drug Application to the FDA by year-end 2023.
Read more →SNDX▲ +7.7%on this news· ran to +19% by day 3shared move
Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials - Data collectively highlight revumenib's combination potential with current standard of care agents and support advancement into pivotal combination ...
Syndax Pharmaceuticals announced positive data from multiple trials of revumenib, a selective oral menin inhibitor, in combination with standard care agents for acute leukemias. The BEAT AML trial showed a 100% complete remission rate, while the SAVE AML trial reported a 78% complete remission rate. Revumenib was well tolerated, supporting its advancement into pivotal trials.
Read more →SNDX▲ +7.7%on this news· ran to +19% by day 3shared move
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease  Trial met its primary e
Incyte and Syndax showcased encouraging results from the Phase 2 AGAVE-201 trial of axatilimab for treating refractory chronic graft-versus-host disease at the ASH Annual Meeting 2023. The trial met its primary endpoint, revealing a 74% overall response rate at the 0.3 mg/kg dose, with significant durable responses observed. The companies plan to file a Biologics License Application for axatilimab by the end of this year, furthering the development of this potential treatment. However, the study also noted treatment-emergent adverse events, with a portion leading to discontinuation of treatment.
Read more →SNDXSyndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals will host an investor event on December 11, 2023, during the 65th ASH Annual Meeting in San Diego. The event will present new data on axatilimab and revumenib, featuring insights from leading experts in hematology. A live webcast will be available for those unable to attend in person.
Read more →SNDXSyndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced that data from its pivotal AUGMENT-101 trial of revumenib will be presented as a late-breaking abstract at the 65th ASH Annual Meeting. The trial demonstrated a 23% complete remission rate in patients with relapsed/refractory KMT2Ar acute leukemia. The company is also preparing for an NDA submission for revumenib by year-end 2023.
Read more →SNDXSyndax Announces Participation at Stifel Healthcare Conference Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals will participate in the Stifel Healthcare Conference on November 14, 2023. CEO Michael A. Metzger is scheduled for a fireside chat at 4:45 p.m. ET. The event will be accessible via a live webcast on the company's website, with a replay available afterward. Syndax is known for its innovative cancer therapy pipeline.
Read more →SNDX▲ +6.2%on this newsshared move
Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update – NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia under RTOR – – mNPM1 final efficacy data from the Phase 1 portion of...
Syndax Pharmaceuticals reported its Q3 2023 financial results, highlighting the initiation of an NDA submission for revumenib in R/R KMT2Ar acute leukemia. The Phase 1 AUGMENT-101 trial showed a 36% CR/CRh rate, and the company is on track for regulatory filings by year-end 2023. Additionally, axatilimab's pivotal trial results will be showcased at the upcoming ASH Annual Meeting.
Read more →SNDX▲ +6.2%on this newsshared move
Syndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced updated data on revumenib, a selective oral menin inhibitor, highlighting its potential as a best-in-class treatment for genetically-defined acute leukemias. The drug demonstrated a 100% overall response rate in the SAVE trial and maintained durable MRD negative responses in post-transplant patients. The company plans to present these findings at the upcoming ASH Annual Meeting and is on track to submit a New Drug Application by year-end.
Read more →SNDX▲ +6.2%on this newsshared move
Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced that results from the pivotal AGAVE-201 trial of axatilimab will be presented at the 65th ASH Annual Meeting. The trial demonstrated promising efficacy and safety in patients with chronic graft-versus-host disease, meeting primary endpoints across all dose cohorts. Syndax and Incyte plan to file a Biologics License Application by the end of 2023.
Read more →SNDX▲ +6.2%on this newsshared move
Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update – NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia under RTOR – – mNPM
Syndax Pharmaceuticals reported robust financial results for the third quarter of 2023 while providing significant updates on their clinical development programs. The company has initiated a New Drug Application for revumenib for relapsed or refractory KMT2Ar acute leukemia under the FDA's Real-time Oncology Review. Recent data from the Phase 1 AUGMENT-101 trial demonstrated a 36% complete remission rate for revumenib in patients with mNPM1 AML. Syndax is on track for potential approvals of revumenib and axatilimab by the end of 2023.
Read more →SNDX▲ +6.6%on this news· ran to +19% by day 3
Syndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023 Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals will announce its third quarter 2023 financial results on November 2, 2023. Following the earnings release, a conference call and webcast will be held at 4:30 p.m. ET to discuss the results and provide a business update. A replay of the event will be available for 90 days post-call.
Read more →SNDXSyndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals plans to submit a New Drug Application for revumenib, a selective oral menin inhibitor, for relapsed/refractory KMT2Ar acute leukemia under the FDA's Real-Time Oncology Review program. This follows positive results from the AUGMENT-101 trial, where revumenib demonstrated significant clinical benefits. The company aims to complete the NDA submission by the end of 2023.
Read more →SNDX▼ -7%on this news
Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis – Trial met its primary endpoint with a CR/CRh rate of 23% at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); an...
Syndax Pharmaceuticals announced that the AUGMENT-101 trial of revumenib in relapsed/refractory KMT2Ar acute leukemia met its primary endpoint, achieving a complete remission rate of 23%. The trial was stopped early for efficacy based on positive interim analysis results. Revumenib showed a favorable safety profile, and Syndax plans to submit an NDA to the FDA by the end of 2023.
Read more →SNDX▼ -7%on this news
Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis – Trial met it
Syndax Pharmaceuticals announced that its pivotal AUGMENT-101 trial of revumenib in treating relapsed/refractory KMT2Ar acute leukemia successfully met its primary endpoint at an interim analysis. The trial showed a complete remission (CR) or CR with partial hematological recovery rate of 23%, leading to the recommendation of stopping further patient accrual. With a favorable safety profile and an overall response rate of 65%, Syndax is positioned to file for FDA approval by the end of 2023. This breakthrough highlights revumenib's potential as a first-in-class therapy for this challenging cancer segment.
Read more →SNDX▼ -7.1%on this news· ran to -22% by day 3shared move
Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023 Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals will announce topline results from the AUGMENT-101 trial, which focuses on relapsed/refractory KMT2Ar acute leukemia, on October 2, 2023. The company will host a conference call and live webcast for investors to discuss these results. A replay will be available for those unable to attend the live event.
Read more →SNDXSyndax Announces Participation at the Citi 18th Annual BioPharma Conference Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals announced that CEO Michael A. Metzger will participate in a panel discussion at the Citi 18th Annual BioPharma Conference on September 6, 2023. The event will include a live webcast available on the company's website. Syndax is known for its innovative cancer therapies, including revumenib and axatilimab.
Read more →SNDXSyndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update – Announced positive topline results from the pivotal AGAVE-201 trial of axatilimab in cGVHD –
Syndax Pharmaceuticals announced its second quarter 2023 financial results and provided updates on its clinical programs. Positive results from the AGAVE-201 trial of axatilimab in chronic graft-versus-host disease (cGVHD) were highlighted, with plans for a Biologics License Application filing by the end of 2023. Additionally, the company remains on track to report pivotal data from the AUGMENT-101 trial of revumenib for acute leukemias within the third quarter. Despite the positive developments, the company reported an increased net loss for the quarter.
Read more →SNDXSyndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals reported its second quarter 2023 financial results, highlighting positive topline data from the AGAVE-201 trial of axatilimab for chronic graft-versus-host disease. The company is also on track to release data from the AUGMENT-101 trial of revumenib for acute leukemia soon. Two U.S. registrational filings are expected by the end of 2023, despite a reported net loss of $44.6 million.
Read more →SNDXSyndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023 Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Syndax Pharmaceuticals will report its second quarter 2023 financial results on August 3, 2023. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. A replay of the call will be available for 90 days post-event.
Read more →SNDXSyndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease – Trial met its primary endpoint across all cohorts wit
Syndax and Incyte have announced positive topline results from the AGAVE-201 trial of axatilimab for chronic graft-versus-host disease (GVHD), with an overall response rate of 74% at the 0.3 mg/kg dose. Notably, 60% of responders maintained their response for over a year. The companies plan to submit a Biologics License Application (BLA) by the end of 2023. Although the results are promising, the study also noted significant adverse events in a portion of participants.
Read more →SNDXSyndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease – Trial met its primary endpoint across all cohorts with an overall response rate (ORR) of 74% at a dose of 0.3 mg/kg administered every two weeks –...
Syndax Pharmaceuticals and Incyte reported positive topline results from the AGAVE-201 trial of axatilimab in chronic graft-versus-host disease (GVHD). The trial achieved its primary endpoint with a 74% overall response rate at a dose of 0.3 mg/kg. Notably, 60% of responders maintained their response after one year. The companies plan to file a Biologics License Application by the end of 2023.
Read more →SNDXSyndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update – Topline data from the pivotal AGAVE-201 trial of axatilimab in cGVHD on track for mid-2023 – &
Syndax Pharmaceuticals reported its financial results for Q1 2023, revealing a net loss of $41.1 million. The company anticipates topline data from pivotal trials for axatilimab and revumenib in the upcoming quarters. Furthermore, it plans to file for U.S. registrational approvals by the end of the year. Increased R&D expenses have raised questions regarding financial sustainability, despite an optimistic pipeline outlook.
Read more →SNDXSyndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development - Neil Gallagher, M.D., Ph.D. brings to Syndax over 20 years of experience as a leading oncology
Syndax Pharmaceuticals has appointed Neil Gallagher, M.D., Ph.D. as President and Head of Research and Development, effective April 10, 2023. Gallagher brings extensive experience from his previous roles, including Chief Medical Officer at AbbVie, where he led oncology development. Syndax is focused on advancing their pipeline, particularly revumenib and axatilimab, which are expected to play crucial roles in their upcoming regulatory submissions and clinical trials. The appointment is seen as a strategic move to bolster the company's growth in targeted oncology.
Read more →SNDXSyndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update – Topline data from AUGMENT-101 KMT2Ar patients expected in the third quarter of 2023 &#
Syndax Pharmaceuticals reported its financial results for Q4 and full year 2022, highlighting significant clinical progress and expected data readouts in 2023. The company anticipates topline data from two pivotal trials, AUGMENT-101 and AGAVE-201, with corresponding regulatory submissions by year-end. Positive Phase 1 results for its drug candidates revumenib and axatilimab were shared, reinforcing their potential to alter treatment paradigms. Despite these advancements, Syndax faced a notable net loss, emphasizing the challenges of clinical development.
Read more →SNDXestimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statement
Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares WALTHAM, Mass., December 14, 2022 (PRNEWSWIRE) Syndax Pharmaceuticals, Inc. ( Syndax, the Company or we ) (Nasdaq: SNDX), a clinical-stage biopharm
Read more →SNDXSyndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer
Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer WALTHAM, Mass., December 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies
Read more →SNDXSyndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update – Updated positive data from Phase 1 portion of AUGMENT-101 trial demonstrates CR/CRh rate of 30% and a
Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update Updated positive data from Phase 1 portion of AUGMENT-101 trial demonstrates CR/CRh rate of 30% and a median durability of response of 9.1 months Enrollment complete in
Read more →SNDXSyndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update – On track to report topline data from revumenib and axatilimab pivotal programs starting in 1H23 
Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update On track to report topline data from revumenib and axatilimab pivotal programs starting in 1H23 Updated data from Phase 1 portion of AUGMENT-101 trial expected in 4Q2
Read more →SNDXSyndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer
Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer WALTHAM, Mass., June 13, 2022 (PRNEWSWIRE) - Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innova
Read more →SNDX▼ -6%on this news
Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update - Topline data from revumenib (SNDX-5613) and axatilimab pivotal programs expected starting in 1H23; Company r
Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update - Topline data from revumenib (SNDX-5613) and axatilimab pivotal programs expected starting in 1H23; Company remains on track for two FDA filings in 2023 - - BEAT-AML a
Read more →SNDXSyndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update - Enrollment remains on track for pivotal programs of SNDX-5613 and axatilimab; topline data expected startin
Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update - Enrollment remains on track for pivotal programs of SNDX-5613 and axatilimab; topline data expected starting in the first half of 2023 - - Initiation of three new
Read more →SNDXSyndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development
Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development WALTHAM, Mass., February 3, 2022 (PRNEWSWIRE) - Syndax Pharmaceuticals, Inc. ("Syndax," the "Compan
Read more →SNDX▲ +9.6%on this news
Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease - 68% overall response rate and broad multiorgan clini
Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease - 68% overall response rate and broad multiorgan clinical benefit observed in highly refractory patients treated
Read more →SNDXunless the context indicates otherwise, references to "Syndax," "the Company," "we," "us," "our" and similar references refer to Syndax Pharmaceuticals, Inc. and its wholly owned subsidiaries. We are dependent upon our c
As used in this Exhibit 99.1, unless the context indicates otherwise, references to "Syndax," "the Company," "we," "us," "our" and similar references refer to Syndax Pharmaceuticals, Inc. and its wholly owned subsidiaries. We are dependent upon our collaboration with Incyte to f
Read more →SNDX▲ +5.1%on this news
Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases - Syndax to receive $152 million in cash ($117 mil
Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases - Syndax to receive $152 million in cash ($117 million upfront plus a $35 million equity investment), with po
Read more →SNDXSyndax Appoints Martin H. Huber, M.D, to its Board of Directors
Syndax Appoints Martin H. Huber, M.D, to its Board of Directors WALTHAM, Mass., September 15, 2021 (PRNEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cance
Read more →SNDXSyndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update - Intermediate doses selected for Phase 2 portion of AUGMENT-101 trial of SNDX-5613 in patients with genetica
Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update - Intermediate doses selected for Phase 2 portion of AUGMENT-101 trial of SNDX-5613 in patients with genetically-defined acute leukemias; updated data from Phase 1 por
Read more →SNDXSyndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update - Today announced two of the prior responders from ongoing Phase 1 portion of AUGMENT-101 trial of SNDX-5613 a
Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update - Today announced two of the prior responders from ongoing Phase 1 portion of AUGMENT-101 trial of SNDX-5613 achieved full count recovery bringing CR/CRh rate up - Co
Read more →SNDXSyndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update - Phase 1 AUGMENT-101 data expected in late 1Q21 or early 2Q21; Phase 2 expansion cohorts expected to commenc
Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update - Phase 1 AUGMENT-101 data expected in late 1Q21 or early 2Q21; Phase 2 expansion cohorts expected to commence in 2Q21 - - Enrollment underway in pivotal Phase 2 AGA
Read more →SNDXunless the context indicates otherwise, references to Syndax, the Company, we, us, our and similar references refer to Syndax Pharmaceuticals, Inc. and its wholly owned subsidiaries. Forward-Looking Statements This docum
As used in this Exhibit 99.1, unless the context indicates otherwise, references to Syndax, the Company, we, us, our and similar references refer to Syndax Pharmaceuticals, Inc. and its wholly owned subsidiaries. Forward-Looking Statements contains forward-looking statements w
Read more →SNDXSyndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update - Presentation of Phase 1 data from AUGMENT-101 trial of SNDX-5613 and initiation of Phase 2 on track for earl
Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update - Presentation of Phase 1 data from AUGMENT-101 trial of SNDX-5613 and initiation of Phase 2 on track for early 2021 - - Company provides update on axatilimab develop
Read more →SNDXSyndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update - Emerging data for SNDX-5613 support several protocol enhancements to AUGMENT- 101 to expand enrollment to p
Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update - Emerging data for SNDX-5613 support several protocol enhancements to AUGMENT- 101 to expand enrollment to pediatric patients and focus exclusively on patients with
Read more →SNDXSyndax's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expe
Syndax Pharmaceuticals Appoints Daphne Karydas as Chief Financial Officer - Richard P. Shea to Retire as Chief Financial Officer - WALTHAM, Mass., July 7, 2020 -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical co
Read more →SNDXSyndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update - Final OS analysis for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected this quarter; pote
Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update - Final OS analysis for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected this quarter; potential NDA filing later this year - - Preliminary Phase 1
Read more →SNDXSyndax Announces Pricing of Public Offering of Common Stock
Syndax Announces Pricing of Public Offering of Common Stock WALTHAM, Mass., April 30, 2020 (PRNEWSWIRE) - Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapi
Read more →SNDXunless the context indicates otherwise, references to "Syndax," "the Company," "we," "us," "our" and similar references refer to Syndax Pharmaceuticals, Inc. and its wholly owned subsidiaries. Forward-Looking Statements
As used in this Exhibit 99.1, unless the context indicates otherwise, references to "Syndax," "the Company," "we," "us," "our" and similar references refer to Syndax Pharmaceuticals, Inc. and its wholly owned subsidiaries. Forward-Looking Statements This document contains forwa
Read more →SNDXSyndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update - Final OS analysis for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q20; potentia
Syndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update - Final OS analysis for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q20; potential NDA filing later this year - - Phase 1 data presentati
Read more →SNDXwhether as a result of new information, future events or otherwise. Company Overview We are a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Our lead product candidate, en
As used in this Exhibit 99.1, unless the context indicates otherwise, references to Syndax, the Company, we, us, our and similar references refer to Syndax Pharmaceuticals, Inc. and its wholly owned subsidiaries. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Exhibit 9
Read more →SNDXforward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials and the rep
Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease - Preliminary Phase 1 results demonstrate inhibition of CSF1R leads to responses in patients with cGvHD - - Phase 2 expansion expected
Read more →SNDXSyndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update - E2112 trial passed final interim OS analysis; trial continues, with final OS analysis expected in 2Q20 - - F
Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update - E2112 trial passed final interim OS analysis; trial continues, with final OS analysis expected in 2Q20 - - First patient dosed in Phase 1/2 AUGMENT-101 trial of SNDX
Read more →SNDXsndx-ex991_6.pptx.htm Corporate presentation | October 2019 Determined to realize a future in which people with cancer live longer and better than ever before Forward-looking statements disclosure This presentation conta
Corporate presentation | October 2019 Determined to realize a future in which people with cancer live longer and better than ever before Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litig
Read more →SNDXSyndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update - IND cleared for SNDX-5613, highly selective menin inhibitor for treatment of MLL-rearranged and NPM1-mutant
Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update - IND cleared for SNDX-5613, highly selective menin inhibitor for treatment of MLL-rearranged and NPM1-mutant acute leukemias - - Final interim OS analysis for E2112
Read more →SNDXSyndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update - E2112 trial passes fourth interim analysis for OS; trial to continue, with next preplanned analysis expected
Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update - E2112 trial passes fourth interim analysis for OS; trial to continue, with next preplanned analysis expected in 4Q19 - - IND filing for targeted menin inhibitor SNDX
Read more →SNDXSyndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update - Next interim OS assessment for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q19
Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update - Next interim OS assessment for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q19 - - IND filing for targeted therapy SNDX-5613, the Compan
Read more →SNDXSyndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update - Next assessment of primary endpoint of overall survival in E2112 trial expected in the second quarter of 201
Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update - Next assessment of primary endpoint of overall survival in E2112 trial expected in the second quarter of 2019 - - Topline data across ENCORE I/O combinations and IND
Read more →SNDXTel 212.600.1902 SNDX-G
Syndax Announces Changes to its Board of Directors - Jennifer Jarrett and William Meury appointed to Board of Directors - - Luke Evnin, Ph.D., and Henry Chen resign as active members - WALTHAM, Mass., September 25, 2018 (PRNEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," t
Read more →SNDXSyndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update - PFS results from pivotal Phase 3 E2112 trial of entinostat plus exemestane in HR+, HER2- breast cancer expe
Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update - PFS results from pivotal Phase 3 E2112 trial of entinostat plus exemestane in HR+, HER2- breast cancer expected in 3Q18 - - Phase 1 trial of SNDX-6352 in chronic gr
Read more →SNDXSyndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update - PFS results from pivotal Phase 3 E2112 trial of entinostat plus exemestane in HR+, HER2- breast cancer expec
Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update - PFS results from pivotal Phase 3 E2112 trial of entinostat plus exemestane in HR+, HER2- breast cancer expected in 3Q18 - - ENCORE 601 data from PD-(L)1 refractory N
Read more →SNDXSyndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update - Phase 2 ENCORE 601 PD-(L)1 refractory melanoma cohort data and melanoma registration strategy disclosure fo
Syndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update - Phase 2 ENCORE 601 PD-(L)1 refractory melanoma cohort data and melanoma registration strategy disclosure forthcoming in 2Q18 - - ENCORE 601 PD-(L)1 refractory NSCLC
Read more →SNDXSyndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update - Pipeline Expanded with Addition of Potential Best-in-Class Menin-MLL-r inhibitors - - Enrollment in First St
Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update - Pipeline Expanded with Addition of Potential Best-in-Class Menin-MLL-r inhibitors - - Enrollment in First Stage of Colorectal and Second Stage of PD-(L)1 Refractory
Read more →SNDXSyndax Expands Pipeline with Exclusive Worldwide License to Allergan s Portfolio of Menin-MLL Inhibitors Compounds Provide Novel Therapeutic Approach for the Potential Treatment of Defined Genetic Subtype of Pediatric an
Syndax Expands Pipeline with Exclusive Worldwide License to Allergan s Portfolio of Menin-MLL Compounds Provide Novel Therapeutic Approach for the Potential Treatment of Defined Genetic Subtype of Pediatric and Adult Acute Leukemias WALTHAM, Mass., October 17, 2017 (PRNEWSWIRE
Read more →SNDXSyndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin - Enrollment of First Patient Triggers $5 Million Mil
Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin - Enrollment of First Patient Triggers $5 Million Milestone Payment to Syndax - WALTHAM, Mass., October 5, 20
Read more →SNDXSyndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update - PD-1 Refractory Melanoma Cohort of ENCORE 601 Completes Enrollment - First Patient Dosed in ENCORE 601 Colo
Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update - PD-1 Refractory Melanoma Cohort of ENCORE 601 Completes Enrollment - First Patient Dosed in ENCORE 601 Colorectal Cancer Cohort - -Company to Host Conference Call T
Read more →SNDXSyndax Prices Public Offering of Common Stock
WALTHAM, Mass., May 24, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a price to the public of $13.25 per share. The gross proceeds to Syndax from this
Read more →SNDXSyndax Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., May 23, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today that it plans to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering. There can be no assurance as to
Read more →SNDXSyndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Advanced Melanoma
-31% objective response rate for first stage of the Phase 2 melanoma cohort of ENCORE 601- -Enrollment ongoing in Stage 2, along with biomarker analysis- -ENCORE 601 now enrolling expanded cohorts of melanoma and NSCLC patients progressed on or after anti-PD1 therapies, after m
Read more →SNDXSyndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies
WALTHAM, Mass., May 16, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today reported that the ENCORE
Read more →SNDXSyndax Pharmaceuticals to Present at the 2017 UBS Global Healthcare Conference
WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Chief Executive Officer Briggs W. Morrison, M.D., will
Read more →SNDXSyndax Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical and Business Update Enrollment of second stage of melanoma cohort in Phase 2 ENCORE 601 trial proceeding ahead of schedule; expect
Syndax Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical and Business Enrollment of second stage of melanoma cohort in Phase 2 ENCORE 601 trial proceeding ahead of schedule; expected to be completed in the third quarter Company to host conferen
Read more →SNDXSyndax to Announce First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 8, 2017
WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its first quarter 2017 financial results on Monday, May 8, 2017, after the close of the U.S. financial markets. In connection with the earnings release, Syndax's management
Read more →SNDXSyndax Announces Expansion of Immuno-Oncology Collaboration Evaluating Entinostat in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Colorectal Cancer
WALTHAM, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), today announced the expansion of ENCORE 601/KEYNOTE 142, the ongoing Phase 2 clinical collaboration with a subsidiary of Merck, known as MSD outside the United States and Canada, to inc
Read more →SNDXSyndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting
WALTHAM, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced a poster presentation hi
Read more →SNDXSyndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors
Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors WALTHAM, Mass., Apr. 4, 2017 (GLOBE NEWSWIRE) Syndax Pharmaceuticals, Inc. ( Syndax, the Company or we ) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on deve
Read more →SNDXSyndax Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting
WALTHAM, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, announces a list of select po
Read more →SNDXSyndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update Encore 601 refractory melanoma cohort to proceed to second stage of Phase 2; pre-specified objec
Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update Encore 601 refractory melanoma cohort to proceed to second stage of Phase 2; pre-specified objective response criteria satisfied Enrollment of the first
Read more →SNDXSyndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its planned participation in three upcoming inve
Read more →SNDXSyndax to Announce Fourth Quarter and Year-end 2016 Financial Results and Host Conference Call and Webcast on March 2, 2017
WALTHAM, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its fourth quarter 2016 financial results on Thursday, March 2, 2017, after the close of the U.S. financial markets. In connection with the earnings release, Syndax's mana
Read more →SNDXSyndax Appoints Richard P. Shea as Chief Financial Officer
Syndax Appoints Richard P. Shea as Chief Financial Officer WALTHAM, Mass., Feb. 9, 2017 (GLOBE NEWSWIRE) Syndax Pharmaceuticals, Inc. ( Syndax, the Company or we ) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multip
Read more →SNDXSyndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board
WALTHAM, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the “Company” or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointmen
Read more →SNDXSyndax Adds Global Pharmaceutical Business Veteran to Board of Directors
WALTHAM, Mass., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the “Company” or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointmen
Read more →SNDXSyndax Pharmaceuticals Announces Collaboration with the National Cancer Institute to Develop Entinostat and SNDX-6352 for the Treatment of Cancer
WALTHAM, Mass., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has entered into a C
Read more →SNDXSyndax Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference
WALTHAM, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Chief Executive Officer Briggs W. Morrison,
Read more →SNDXSyndax Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update Execution on clinical timelines and advancement of oncology programs continues with initiation of: Phase 2 cohorts of ENCOR
Syndax Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update Execution on clinical timelines and advancement of oncology programs continues with initiation of: WALTHAM, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) Syndax Pharmaceuticals, Inc. ( Syn
Read more →SNDXSyndax Pharmaceuticals to Present at the SITC 31st Annual Scientific Meeting
WALTHAM, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced six poster pre
Read more →SNDXSyndax to Announce Third Quarter 2016 Financial Results and Host Conference Call and Webcast on November 10, 2016
WALTHAM, Mass., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its third quarter 2016 financial results on Thursday, November 10, 2016, after the close of the U.S. financial markets. In connection with the earnings release, Syndax's m
Read more →SNDXSyndax Pharmaceuticals Announces Participation at Four Upcoming Investor Conferences
WALTHAM, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its planned participation in four upcoming inve
Read more →SNDXSyndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update Expanded pipeline with potentially best-in-class, IND-ready anti-CSF-1R antibody Progressing to Phase 2 of ENCORE 601 in N
Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update Expanded pipeline with potentially best-in-class, IND-ready anti-CSF-1R antibody Progressing to Phase 2 of ENCORE 601 in NSCLC and Melanoma Initiated ENCORE 602 for TNBC in collab
Read more →SNDXSyndax Appoints Leading Experts to Scientific Advisory Board (SAB)
WALTHAM, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on the development of novel anti-cancer therapies, announced the appointment of seven leading oncology experts to its Scientific Adviso
Read more →SNDXSyndax to Announce Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 9, 2016
WALTHAM, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its second quarter 2016 financial results on Tuesday, August 9, 2016, before the opening of the U.S. financial markets. In connection with the earnings release, Syndax’s m
Read more →SNDXSyndax Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
WALTHAM, Mass., July 07, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy across multiple cancer indications, today announced that Chief Executive Officer, Bri
Read more →SNDXSyndax Expands Pipeline With Exclusive Worldwide License Agreement for UCB s Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program IND-ready immuno-oncology agent has best in class potential
Syndax Expands Pipeline With Exclusive Worldwide License Agreement for UCB s Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program IND-ready immuno-oncology agent has best in class potential WALTHAM, Mass., July 06, 2016 (GLOBE NEWSWIRE) Syndax Pharmaceuticals, Inc. (
Read more →SNDXSyndax Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat broadly as a combination therapy across multiple cancer indications, today announced that President and Chief
Read more →SNDXENTINOSTAT DATA TO BE HIGHLIGHTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2016
ENTINOSTAT DATA TO BE HIGHLIGHTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2016 ANNUAL MEETING WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in mul
Read more →SNDXSyndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO ENCORE 601 Phase 1b dose escalation has been completed and safety confirmation has commenced at the 5 mg dose
Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO ENCORE 601 Phase 1b dose escalation has been completed and safety confirmation has commenced at the 5 mg dose Waltham, Massachusetts May 16, 2016 (GLOBE NEWSWIRE): Syn
Read more →SNDXSyndax to Announce First Quarter 2016 Financial Results and Host Conference Call and Live Webcast on May 16, 2016
WALTHAM, Mass., April 26, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its first quarter 2016 financial results on Monday, May 16, 2016, after the closing of the U.S. financial markets. In connection with the earnings release, Syndax’s manag
Read more →SNDXSyndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting
WALTHAM, Mass., April 11, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, announced today that entinostat will be the subject of seven investigator pre
Read more →SNDXSyndax Pharmaceuticals, Inc. (Nasdaq:SNDX) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
ADVISORY, March 03, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, will visit the Nasdaq MarketSite in Times Square to celebrate its initial public o
Read more →SNDXSyndax Announces Pricing of Initial Public Offering
WALTHAM, Mass., March 02, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, announced today that it has priced its initial public offering of 4,400,000 shares of its c
Read more →Competitive Position
How SNDX ranks across every disease it competes inCompetitive Position is a premium feature
See how SNDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial